Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study

MLA

Maul, Julia-Tatjana, et al. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. Jan. 2021. EBSCOhost, https://doi.org/10.5167/uzh-209564.

APA

Maul, J.-T., Distler, M., Kolios, A., Maul, L. V., Guillet, C., Graf, N., Imhof, L., Lang, C., Navarini, A. A., & Schmid-Grendelmeier, P. (2021). Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. https://doi.org/10.5167/uzh-209564

Chicago

Maul, Julia-Tatjana, Meike Distler, Antonios Kolios, Lara Valeska Maul, Carole Guillet, Nicole Graf, Laurence Imhof, Claudia Lang, Alexander A Navarini, and Peter Schmid-Grendelmeier. 2021. “Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study,” January. doi:10.5167/uzh-209564.